| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Urtoxazumab (DXX00501)
CAS:502496-16-4
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Urtoxazumab
CAS:502496-16-4
Purity:95.00% Package:1mg;5mg
|
| Company Name: |
Changsha Fuzhen Biotechnology Co.，LTD
|
| Tel: |
0731-13823398 15111215862 |
| Email: |
313359644@qq.com |
| Products Intro: |
Product Name:Urtoxazumab
CAS:502496-16-4
Purity:95.00% Package:100ug 500ug 1mg 5mg
|
|
| | Urtoxazumab Basic information |
| Product Name: | Urtoxazumab | | Synonyms: | Urtoxazumab;Research Grade Urtoxazumab (DXX00501);Research Grade Urtoxazumab | | CAS: | 502496-16-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Urtoxazumab Structure]() |
| | Urtoxazumab Chemical Properties |
| | Urtoxazumab Usage And Synthesis |
| Uses | Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2[1]. | | in vivo | Urtoxazumab (TMA-15) (0.25-2.5 mg/kg; i.v.; once) ameliorates the lethal challenge in a time- and dose- dependent manner in B2F1-infected mice[1]. | Animal Model: | 5-week-old male DBA/2J mice, STEC B2F1-infection model[1] | | Dosage: | 0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg | | Administration: | Intravenous administration, 1 h before and 12, 24, and 48 h after infection | | Result: | Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection. |
| | References | [1] Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42. DOI:10.1086/323082 |
| | Urtoxazumab Preparation Products And Raw materials |
|